Removal of Fkbp12/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 7, 2007, Pages 1580-1586

  Long, Cheng ^a   Cook, Leslie G ^a   Wu, Gang Yi ^a   Mitchell, Brett M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Endothelium; Experimental; Hypertension; Nitric oxide; Ryanodine receptors

Indexed keywords

FK 506 BINDING PROTEIN; FK506 BINDING PROTEIN 12; FK506 BINDING PROTEIN 12.6; ISOPROTEIN; NITRIC OXIDE; RAPAMYCIN; RYANODINE; RYANODINE RECEPTOR; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; BLOOD PRESSURE REGULATION; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HYPERTENSION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ANIMALS; CALCIUM CHANNELS; CALCIUM SIGNALING; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE DELETION; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SENSITIVITY AND SPECIFICITY; SIROLIMUS; TACROLIMUS; TACROLIMUS BINDING PROTEIN 1A; VASOCONSTRICTION; VASODILATION;

EID: 34250791617     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.144808     Document Type: Article

References (28)

1. Jayaraman T, Brillantes AM, Timerman AP, Fleischer S, Erdjument-Bromage H, Tempst P, Marks AR. FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem. 1992;267:9474-9477.
2. Timerman AP, Jayaraman T, Wiederrecht G, Onoue H, Marks AR, Fleischer S. The ryanodine receptor from canine heart sarcoplasmic reticulum is associated with a novel FK-506 binding protein. Biochem Biophys Res Commun. 1994;198:701-706.
3. Timerman AP, Ogunbunmi E, Freund E, Wiederrecht G, Marks AR, Fleischer S. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506 binding protein. J Biol Chem. 1993;268:22992-22999.
4. Brillantes AB, Ondrias K, Scott A, Kobrinsky E, Ondriasova E, Moschella MC, Jayaraman T, Landers M, Ehrlich BE, Marks AR. Stabilization of calcium release channel (ryanodine receptor) function by FK-506 binding protein. Cell. 1994;77:513-523.
5. Chen SRW, Chang L, MacLennan DH. Assymetrical blockade of the Ca release channel (ryanodine receptor) by 12-kDa FK-506 binding protein. Proc Natl Acad Sci U S A. 1994;91:11953-11957.
6. Timerman AP, Onoue H, Xin HB, Barg S, Copello J, Wiederrecht G, Fleischer S. Selective binding of FKBP12.6 by the cardiac ryanodine receptor. J Biol Chem. 1996;271:20385-20391.
7. Xin HB, Rogers K, Qi Y, Kanematsu T, Fleischer S. Three amino acid residues determine selective binding of FK506-binding protein 12.6 to the cardiac ryanodine receptor. J Biol Chem. 1999;274:15315-15319.
8. Ahern GP, Junankar PR, Dulhunty AF. Single channel activity of the ryanodine receptor calcium release channel is modulated by FK-506. FEBS Lett. 1994;352:369-374.
9. 2+-release channels from cardiac muscle. Circ Res. 1996;78:990-997.
10. Wehrens XH, Lehnart SE, Reiken SR, Deng SX, Vest JA, Cervantes D, Coromilas J, Landry DW, Marks AR. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science. 2004;304:292-296.
11. 2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1. Biophys J. 2004;87:3193-3204.
12. 2+ signaling in HEK-293 and skeletal muscle cells expressing recombinant ryanodine receptors harboring malignant hyperthermia and central core disease mutations. J Biol Chem. 2005;280:15380-15389.
13. Lindenfeld J, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel EE, Mestroni L, Page RL, Kobashigawa J. Drug therapy in the heart transplant recipient - Part II: Immunosuppressive drugs. Circulation. 2004;110:3858-3865.
14. Lindenfeld J, Page RL, Zolty R, Shakar SF, Levi M, Lowes BD, Wolfel EE, Miller GG. Drug therapy in the heart transplant recipient - Part III: Common medical problems. Circulation. 2005;111:113-117.
15. Takeda Y, Miyamori I, Furukawa K, Inaba S, Mabuchi H. Mechanisms of FK 506-induced hypertension in the rat. Hypertension. 1999;33:130-136.
16. Xin HB, Senbonmatsu T, Cheng DS, Wang YX, Copello JA, Ji GJ, Collier ML, Deng KY, Jeyakumar LH, Magnuson MA, Inagami T, Kotlikoff MI, Fleischer S. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature. 2002;416:334-337.
17. Jiang XH, Yang F, Tan HM, Liao D, Bryan RM Jr., Durante W, Rumbaut RE, Yang XF, Wang H. Hyperhomocysteinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol. 2005;25:2515-2521.
18. Long C, Cook LG, Hamilton SL, Wu GY, Mitchell BM. FK506 binding protein 12/12.6 depletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure. Hypertension. 2007;49:569 -576.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
20. Dominiczak AF, Bohr DF. Nitric oxide and its putative role in hypertension. Hypertension. 1995;25:1202-1211.
21. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther. 2001;299:818-824.
22. Hirata KI, Kuroda R, Sakoda T, Katayama M, Inoue N, Suematsu M, Kawashima S, Yokoyama M. Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension. 1995;25:180-185.
23. 2+/Calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res. 2001;88:e68-e75.
24. Epstein A, Beall A, Wynn J, Mulloy L, Brophy CM. Cyclosporine, but not FK506, selectively induces renal and coronary artery smooth muscle contraction. Surgery. 1998;123:456-460.
25. De Lima JJG, Xue H, Coburn L, Andoh TF, McCarron DA, Bennett WM, Roullet JB. Effects of FK506 in rat and human resistance arteries. Kidney Int. 1999;55:1518-1527.
26. Tang WX, Chen YF, Zou AP, Campbell WB, Li PL. Role of FKBP12.6 in cADPR-induced activation of reconstituted ryanodine receptors from arterial smooth muscle. Am J Physiol Heart Circ Physiol. 2002;282:H1304-H1310.
27. Ji G, Feldman ME, Greene KS, Sorrentino V, Xin HB, Kotlikoff MI. RYR2 proteins contribute to the formation of Ca2+ sparks in smooth muscle. J Gen Physiol. 2004;123:377-386.
28. Wang YX, Zheng YM, Mei QB, Wang QS, Collier ML, Fleischer S, Xin HB, Kotlikoff MI. FKBP12.6 and cADPR regulation of Ca2+ release in smooth muscle cells. Am J Cell Physiol. 2004;286:C538-C546.